Cargando…
Reply to “Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS”
Autores principales: | Bischof, Antje, Papinutto, Nico, Keshavan, Anisha, Rajesh, Anand, Kirkish, Gina, Zhang, Xinheng, Mallott, Jacob M., Asteggiano, Carlo, Sacco, Simone, Gundel, Tristan J., Zhao, Chao, Stern, William A., Caverzasi, Eduardo, Zhou, Yifan, Gomez, Refujia, Ragan, Nicholas R., Santaniello, Adam, Zhu, Alyssa H., Juwono, Jeremy, Bevan, Carolyn J., Bove, Riley M., Crabtree‐Hartman, Elizabeth, Gelfand, Jeffrey M., Goodin, Douglas S., Graves, Jennifer S., Green, Ari J., Oksenberg, Jorge R., Waubant, Emmanuelle, Wilson, Michael R., Zamvil, Scott S., Cree, Bruce A., Hauser, Stephen L., Henry, Roland G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511767/ https://www.ncbi.nlm.nih.gov/pubmed/35233827 http://dx.doi.org/10.1002/ana.26340 |
Ejemplares similares
-
Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis
por: Bischof, Antje, et al.
Publicado: (2022) -
Silent progression in disease activity–free relapsing multiple sclerosis
por: Cree, Bruce A. C., et al.
Publicado: (2019) -
Association of daily physical activity with brain volumes and
cervical spinal cord areas in multiple sclerosis
por: Block, Valerie J, et al.
Publicado: (2022) -
MWF of the corpus callosum is a robust measure of remyelination: Results from the ReBUILD trial
por: Caverzasi, Eduardo, et al.
Publicado: (2023) -
A Precision Medicine Tool for Patients With Multiple Sclerosis (the Open MS BioScreen): Human-Centered Design and Development
por: Schleimer, Erica, et al.
Publicado: (2020)